These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 10391004)

  • 1. [Virological response to interferon therapy in patients dually infected with TT virus and hepatitis C virus].
    Matsumoto H; Araki M; Kakinuma K; Kawamata O; Yamauchi T
    Nihon Rinsho; 1999 Jun; 57(6):1387-9. PubMed ID: 10391004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
    Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of TT virus superinfection in patients with chronic hepatitis C.
    Watanabe H; Saito T; Kawamata O; Shao L; Aoki M; Terui Y; Mitsuhashi H; Matsuo T; Takeda Y; Saito K; Togashi H; Shinzawa H; Takahashi T
    Am J Gastroenterol; 2000 Jul; 95(7):1776-80. PubMed ID: 10925984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Susceptibility of TT virus to interferon therapy].
    Chayama K
    Nihon Rinsho; 1999 Jun; 57(6):1390-4. PubMed ID: 10391005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Viral co-infections in hepatitis C: HBV, HBV-C/HGV and TTV studies].
    Pár A; Takács M; Brojnás J; Berencsi G; Paál M; Horányi M; Miseta A; Hegedüs G; Mózsik G; Hunyady B
    Orv Hetil; 2004 May; 145(19):987-92. PubMed ID: 15181733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C.
    Umemura T; Alter HJ; Tanaka E; Orii K; Yeo AE; Shih JW; Matsumoto A; Yoshizawa K; Kiyosawa K
    Hepatology; 2002 Apr; 35(4):953-9. PubMed ID: 11915044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C and G co-infection: response to interferon therapy and quantitative changes in serum HGV-RNA.
    McHutchison JG; Nainan OV; Alter MJ; Sedghi-Vaziri A; Detmer J; Collins M; Kolberg J
    Hepatology; 1997 Nov; 26(5):1322-7. PubMed ID: 9362379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interferon treatment for hepatitis G virus infection in patients with chronic hepatitis C].
    Baba T; Makino R; Shibata M; Harada E; Mitamura K
    Nihon Rinsho; 1997 Mar; 55(3):625-30. PubMed ID: 9086771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HGV and TTV - new hepatitis viruses].
    Loginov AS; Sharafanova TI; Reshetniak VI; Il'chenko LIu; Shepeleva SD; Serova TI; Tkachev VD
    Ter Arkh; 2000; 72(11):9-13. PubMed ID: 11270960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
    Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
    Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.
    Rocha CM; Perez RM; Narciso JL; Ferreira AP; Lemos LB; Medina-Pestana JO; Silva AE; Ferraz ML
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):119-23. PubMed ID: 17272996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level.
    Yamada G; Takatani M; Kishi F; Takahashi M; Doi T; Tsuji T; Shin S; Tanno M; Urdea MS; Kolberg JA
    Hepatology; 1995 Nov; 22(5):1351-4. PubMed ID: 7590646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Seroepidemiological survey of TT virus (TTV) infection in an endemic area for hepatitis C virus].
    Sugiyama T; Shimizu M; Yamauchi O; Kojima M
    Nihon Rinsho; 1999 Jun; 57(6):1402-5. PubMed ID: 10391007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose interferon-alpha 2b plus ribavirin combination therapy for GB virus-C/hepatitis G virus infection--a study in patients with chronic hepatitis C.
    Cheng PN; Jen CM; Young KC; Chen CY; Lu SN; Wang CS; Chang TT
    Hepatogastroenterology; 2003; 50(50):449-52. PubMed ID: 12749244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between TT virus infection and hepatitis C virus response to interferon therapy in doubly infected patients.
    Maggi F; Fornai C; Tempestini E; Andreoli E; Lanini L; Vatteroni ML; Pistello M; Marchi S; Antonelli G; Bendinelli M
    J Biol Regul Homeost Agents; 2003; 17(2):176-82. PubMed ID: 14518719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
    Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
    J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes.
    Todros L; Saracco G; Durazzo M; Abate ML; Touscoz G; Scaglione L; Verme G; Rizzetto M
    Hepatology; 1995 Nov; 22(5):1374-8. PubMed ID: 7590650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.